ArticleAmerican journal of physiology. Lung cellular and molecular physiology2018
Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists.
Article in American journal of physiology. Lung cellular and molecular physiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Heritable pulmonary arterial hypertension: new genetic findings and environmental triggers.Scientific reports · 2026Article
- Drugs and toxins associated with pulmonary arterial hypertension: from established culprits to novel threats.ERJ open research · 2025Review
- Trends and patterns in pulmonary arterial hypertension-associated hospital admissions among methamphetamine users: a decade-long study.Frontiers in cardiovascular medicine · 2024Article
- Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis.British journal of clinical pharmacology · 2022Article
- Social determinants of health in pulmonary arterial hypertension patients in the United States: Clinician perspective and health policy implications.Pulmonary circulation · 2022Article
- The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure.Circulation research · 2022Review
- Role of environmental toxicants in the development of hypertensive and cardiovascular diseases.Toxicology reports · 2022Review
- Ion channels as convergence points in the pathology of pulmonary arterial hypertension.Biochemical Society transactions · 2021Review
- Sex-dependent right ventricular hypertrophic gene changes after methamphetamine treatment in mice.European journal of pharmacology · 2021Article
- The hallmarks of severe pulmonary arterial hypertension: the cancer hypothesis-ten years later.American journal of physiology. Lung cellular and molecular physiology · 2020Review
- Pulmonary hypertension: From an orphan disease to a global epidemic.Global cardiology science & practice · 2020Review
- Pulmonary arterial hypertension in breast cancer patients on HER2-targeted therapy: a review of FDA Adverse Events Reporting System data.ERJ open research · 2020Article
- Impact of Nutrition on Pulmonary Arterial Hypertension.Nutrients · 2020Review
- Infection in pulmonary vascular diseases: Would another consortium really be the way to go?Global cardiology science & practice · 2019Article
- Methamphetamine and the risk of pulmonary arterial hypertension.Current opinion in pulmonary medicine · 2018Review
- Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension.International journal of clinical pharmacy · 2018Article
- "Anagrelide-induced pulmonary arterial hypertension": a rare case of drug-induced pulmonary arterial hypertension.Pulmonary circulationArticle
- Sugen-morphine model of pulmonary arterial hypertension.Pulmonary circulationArticle
- High geographic prevalence of pulmonary artery hypertension: associations with ethnicity, drug use, and altitude.Pulmonary circulationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Drug-induced pulmonary arterial hypertension (D-PAH) is a form of World Health Organization Group 1 pulmonary hypertension (PH) defined by severe small vessel loss and obstructive vasculopathy, which leads to progressive right heart failure and death. To date, 16 different compounds have been associated with D-PAH, including anorexigens, recreational stimulants, and more recently, several Food and Drug Administration-approved medications. Although the clinical manifestation, pathology, and hemodynamic profile of D-PAH are indistinguishable from other forms of pulmonary arterial hypertension, its clinical course can be unpredictable and to some degree dependent on removal of the offending agent. Because only a subset of individuals develop D-PAH, it is probable that genetic susceptibilities play a role in the pathogenesis, but the characterization of the genetic factors responsible for these susceptibilities remains rudimentary. Besides aggressive treatment with PH-specific therapies, the major challenge in the management of D-PAH remains the early identification of compounds capable of injuring the pulmonary circulation in susceptible individuals. The implementation of pharmacovigilance, precision medicine strategies, and global warning systems will help facilitate the identification of high-risk drugs and incentivize regulatory strategies to prevent further outbreaks of D-PAH. The goal for this review is to inform clinicians and scientists of the prevalence of D-PAH and to highlight the growing number of common drugs that have been associated with the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.